X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (269) 269
cardiac & cardiovascular systems (215) 215
male (187) 187
female (185) 185
aged (160) 160
middle aged (154) 154
treatment outcome (103) 103
cardiovascular (92) 92
acute coronary syndromes (71) 71
risk factors (70) 70
percutaneous coronary intervention (69) 69
heart attacks (66) 66
mortality (63) 63
myocardial infarction - therapy (63) 63
myocardial infarction (62) 62
abridged index medicus (60) 60
time factors (53) 53
aspirin (48) 48
prospective studies (48) 48
cardiology and cardiovascular medicine (47) 47
adult (46) 46
cardiology (45) 45
follow-up studies (45) 45
guidelines (45) 45
clopidogrel (43) 43
prognosis (41) 41
cardiac patients (40) 40
coronary heart disease (40) 40
outcomes (39) 39
drug therapy (38) 38
platelet aggregation inhibitors - therapeutic use (38) 38
risk assessment (38) 38
electrocardiography (36) 36
myocardial infarction - mortality (36) 36
aged, 80 and over (35) 35
care and treatment (35) 35
coronary angiography (35) 35
double-blind method (35) 35
stents (34) 34
thrombosis (33) 33
acute coronary syndrome (32) 32
angioplasty (32) 32
internal medicine (32) 32
cardiovascular disease (31) 31
drug-eluting stents (31) 31
heart failure (31) 31
acute myocardial-infarction (30) 30
peripheral vascular disease (30) 30
stroke (30) 30
therapy (30) 30
acute myocardial infarction (29) 29
intervention (29) 29
medical and health sciences (29) 29
medicin och hälsovetenskap (29) 29
management (28) 28
angioplasty, balloon, coronary (27) 27
cardiovascular diseases (27) 27
coronary artery bypass (27) 27
medicine, general & internal (27) 27
patients (27) 27
platelet aggregation inhibitors - administration & dosage (26) 26
acute coronary syndrome - therapy (25) 25
antiplatelet therapy (25) 25
clinical trials (24) 24
europe (24) 24
hemorrhage - chemically induced (24) 24
kaplan-meier estimate (24) 24
myocardial-infarction (24) 24
clinical medicine (23) 23
heart attack (23) 23
medical imaging (23) 23
patient outcomes (23) 23
platelet aggregation inhibitors - adverse effects (23) 23
prasugrel (23) 23
ticlopidine - analogs & derivatives (23) 23
coronary vessels (22) 22
incidence (22) 22
risk (22) 22
stent (22) 22
surgery (22) 22
ticagrelor (22) 22
trial (22) 22
hospital mortality (21) 21
kardiologi (21) 21
medical research (21) 21
st-segment elevation (21) 21
analysis (20) 20
blood pressure (20) 20
cardiac and cardiovascular systems (20) 20
disease (20) 20
heart (20) 20
myocardial infarction - diagnosis (20) 20
registries (20) 20
task-force (20) 20
thrombolysis (20) 20
acute coronary syndrome - drug therapy (19) 19
acute disease (19) 19
angioplasty, balloon, coronary - methods (19) 19
atrial fibrillation (19) 19
klinisk medicin (19) 19
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (550) 550
Czech (23) 23
Spanish (9) 9
Polish (5) 5
Portuguese (5) 5
Turkish (4) 4
Italian (2) 2
Russian (2) 2
Japanese (1) 1
Norwegian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European heart journal, ISSN 0195-668X, 02/2017, Volume 38, Issue 8, pp. 533 - 534
Journal Article
European heart journal, ISSN 1522-9645, 2008, Volume 29, Issue 12, pp. 1495 - 1503
Journal Article
Heart and Vessels, ISSN 0910-8327, 6/2016, Volume 31, Issue 6, pp. 841 - 845
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2011, Volume 377, Issue 9775, pp. 1409 - 1420
Journal Article
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2012, Volume 366, Issue 1, pp. 20 - 33
In this trial, vorapaxar, a protease-activated–receptor 1 antagonist that inhibits thrombin-induced platelet activation, was not effective in reducing the... 
MEDICINE, GENERAL & INTERNAL | PLACEBO | GLYCOPROTEIN IIB/IIIA INHIBITORS | CLOPIDOGREL | TASK-FORCE | SAFETY | DOUBLE-BLIND | ANTIPLATELET THERAPY | Follow-Up Studies | Angioplasty | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Pyridines - adverse effects | Cardiovascular Diseases - mortality | Female | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Pyridines - therapeutic use | Double-Blind Method | Receptor, PAR-1 - antagonists & inhibitors | Kaplan-Meier Estimate | Combined Modality Therapy | Lactones - adverse effects | Lactones - therapeutic use | Acute Coronary Syndrome - drug therapy | Intracranial Hemorrhages - chemically induced | Coronary Artery Bypass | Acute Coronary Syndrome - therapy | Aged | Hemorrhage - chemically induced | Antagonists (Biochemistry) | Drugs | Dose-response relationship (Biochemistry) | Dosage and administration | Product/Service Evaluations | Drug therapy | Coronary heart disease | Myocardial infarction | Cerebral infarction | Stroke | Heart attacks | Proteinase-activated receptor 1 | Thrombin | Cardiovascular disease | Hemorrhage | Bleeding | Investigations | Manuscripts | Ischemia | Blood platelets | Acute coronary syndromes | Research centers | Malalties cardiovasculars | Bypass cardiopulmonar | Medicaments | Bypass cardiopulmonary | Plaquetes sanguínies | Cardiovascular diseases
Journal Article
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2013, Volume 368, Issue 14, pp. 1303 - 1313
This clinical trial compared two antiplatelet regimens during PCI: oral clopidogrel and intravenous cangrelor. As compared with clopidogrel, cangrelor resulted... 
no | MEDICINE, GENERAL & INTERNAL | PERCUTANEOUS CORONARY INTERVENTION | METAANALYSIS | TICAGRELOR | CARDIOVASCULAR EVENTS | ACHIEVE OPTIMAL MANAGEMENT | CLOPIDOGREL PRETREATMENT | PRASUGREL | STANDARD THERAPY | ANTIPLATELET THERAPY | STRATEGIES | Double-Blind Method | Ticlopidine - therapeutic use | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Adenosine Monophosphate - therapeutic use | Ticlopidine - analogs & derivatives | Adenosine Monophosphate - adverse effects | Angioplasty, Balloon, Coronary - adverse effects | Adenosine Monophosphate - analogs & derivatives | Hemorrhage - etiology | Intention to Treat Analysis | Myocardial Ischemia - therapy | Ticlopidine - adverse effects | Female | Aged | Myocardial Ischemia - mortality | Thrombosis - prevention & control | Platelet Aggregation Inhibitors - therapeutic use | Stents - adverse effects | Thrombosis - mortality | Platelet Aggregation Inhibitors - adverse effects | Drugs | Dose-response relationship (Biochemistry) | Usage | Cangrelor | Angioplasty | Patient outcomes | Product/Service Evaluations | Hemorrhage | Risk factors | Control | Ischemia | Dosage and administration | Drug therapy | Myocardial infarction | Adenosine | Heart attacks | Intravenous administration | Thrombosis | Patients | Bleeding | Dyspnea | Implants | Clopidogrel | Acute coronary syndromes | Respiration
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2010, Volume 376, Issue 9748, pp. 1233 - 1243
Journal Article